Galectin Therapeutics Inc.

Galectin Therapeutics Inc. is a clinical stage biopharmaceutical company specializing in the research and development of therapies for fibrotic, cancer, and other diseases. The company's primary focus is on the development of belapectin (GR-MD-02), a galectin-3 inhibitor, currently in Phase III clinical trials for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for cancer treatment. Additionally, the company is working on GM-CT-01 for cardiac and vascular fibrosis. Galectin Therapeutics Inc. also collaborates on the research and development of small organic molecule inhibitors of galectin-3 for oral administration through its joint venture, Galectin Sciences, LLC.

Products

• Belapectin (GR-MD-02) for liver fibrosis and cancer treatment

• GM-CT-01 for cardiac and vascular fibrosis